


Form PTO/SB/08 INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary) 	Docket Number (Optional) GPCG-P01-003	Application Number 10/001,934
	Applicant Nagy et al.	
	Filing Date November 15, 2001	Group Art Unit 1642

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

RECEIVED

FEB 07 2003

TECH CENTER 1600/2901


FOREIGN PATENT DOCUMENTS


	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
						YES	NO
KAC	AA	WO 99/45031	9/10/99	WIPO			



OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages Etc.)

KAC	AB	Ackerman, R.C. et al. Induction of apoptotic or lytic death in an ovarian adenocarcinoma cell line by antibodies generated against a synthetic N-terminal extracellular domain gonadotropin-releasing hormone receptor peptide. <i>Cancer Letters</i> 81, 177-184 (1994).
	AC	Billing, R. & Chatterjee, S. Prolongation of Skin Allograft Survival in Monkeys Treated with Anti-Ia and Anti-Blast / Monocyte Monoclonal Antibodies. <i>Transplant. Proc.</i> 15, 649 (1983).
	AD	Bonagura, V.R. et al. Anti-clonotypic Autoantibodies in Pregnancy. <i>Cell. Immunol.</i> 108, 356 (1987).
	AE	Bunce, M. et al. The production of a human monoclonal antibody defining a split of HLA-DRw13 (DRw13b). <i>Tissue Antigens</i> 36, 100-102 (Sept. 1990).
	AF	DeNardo, S.J. et al. Treatment of B Cell Malignancies with 131I Lym-1 Monoclonal Antibodies. <i>Int. J. Cancer Suppl.</i> 3, 96-101 (1988).
	AG	Dueymes, M. et al. Anti-Endothelial Cell Antibody Binding Causes Apoptosis of Endothelial Cells. <i>Arthritis & Rheumatism</i> 40, S103 (Sept. 1997).
	AH	Dyer, M.J.S. et al. Effects of CAMPATH-1 Antibodies in Vivo in Patients with Lymphoid Malignancies: Influence of Antibody Isotype. <i>Blood</i> 73, 1431-1439 (1989).
	AI	Dyer, M.J.S. The Role of CAMPATH-I Antibodies in the Treatment of Lymphoid Malignancies. <i>Seminars in Oncology</i> 26, Suppl. 14, 52-57 (Oct. 1999).
	AJ	Epstein, A.L. et al. Two New Monoclonal Antibodies, Lym-1 and Lym-2, Reactive with Human B-Lymphocytes and Derived Tumors, with Immunodiagnostic and Immunotherapeutic Potential. <i>Cancer Res.</i> 47, 830-840 (1987).
	AK	Eray, M. et al. Cross-linking of surface IgG induces apoptosis in a bcl-2 expressing human follicular lymphoma line of mature B cell phenotype. <i>Int. Immunol.</i> 6, 1817-1827 (1994).
✓	AL	Ghahremani, M. et al. Activation of Fas Ligand/Receptor System Kills Ovarian Cancer Cell Lines by an Apoptotic Mechanism. <i>Gynecologic Oncol.</i> 70, 275-281 (1998).

Form PTO/SB/08		Docket Number (Optional) GPCG-P01-003	Application Number 10/001,934
INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>		Applicant Nagy et al.	
		Filing Date November 15, 2001	Group Art Unit 1642
		Gingrich, R.D. et al. Identification and Characterization of a New Surface Membrane Antigen Found Predominantly on Malignant B Lymphocytes. <i>Blood</i> 75, 2375-2387 (1990).	
		Harrison, J.L. et al. Screening of Phage Antibody Libraries. <i>Methods Enzymol.</i> 267, 83-109 (1996).	
	AO	Hata, H. et al. Fas/Apo-1 (CD95)-Mediated and CD95-Independent Apoptosis of Malignant Plasma Cells. <i>Leukemia and Lymphoma</i> 24, 35-42 (1996).	
	AP	Hayakawa, A. et al. A short peptide derived from the antisense homology box of Fas ligand induces apoptosis in anti-Fas antibody-insensitive human ovarian cancer cells. <i>Apoptosis</i> 5, 37-41 (2000).	
	AQ	Hensel, F. et al. Characterization of Glycosylphosphatidylinositol-linked Molecule CD55/Decay-accelerating Factor as the Receptor for Antibody SC-1-induced Apoptosis. <i>Cancer Res.</i> 59, 5299-5306 (15 Oct. 1999).	
	AR	Higashigawa, M. et al. FK506 inhibits anti-IgM antibody-induced apoptosis and 17kD endonuclease activity in the human B-cell line, MBC-1, established from Burkitt's lymphoma. <i>Br. J. Haematology</i> 99, 908-913 (Dec. 1997).	
	AS	Hoess, A. et al. Generation of human antibodies that selectively recognize diseased cells overexpressing surface bound antigens.	
	AT	Ikewaki, N. et al. Development and characterization of a human monoclonal antibody probably detecting the leukocyte differentiation antigen CD39. <i>Tissue Antigens</i> 39, 174-181 (April 1992).	
	AU	Ishizuka, H. et al. Antitumour Activity of Murine Monoclonal Antibody NCC-ST-421 on Human Cancer Cells by Inducing Apoptosis. <i>Cancer Res.</i> 58, 2513-2518 (1998).	
	AV	Jones, P.T. et al. Replacing the complementarity-determining regions in a human antibody with those from a mouse. <i>Nature</i> 321, 522-525 (1986).	
	AW	Jonker, M. et al. Complications of Monoclonal Antibody (MAb) Therapy: The Importance of Primate Studies. <i>Transplant. Proc.</i> 23, 264 (1991).	
	AX	Kim, C.H. et al. Altered expression of the genes regulating apoptosis in multidrug resistant human myeloid leukemia cell lines overexpressing MDR1 or MRP gene. <i>Int. J. Oncol.</i> 11, 945-950 (1997).	
	AY	Knappik, A. et al. Fully Synthetic Human Combinatorial Antibody Libraries (HuCAL) Based on Modular Consensus Frameworks and CDRs Randomized with Trinucleotides. <i>J. Mol. Biol.</i> 296, 57-86 (11 Feb. 2000).	
	AZ	Lee, J.W. et al. HLA-DR-Mediated Signals for Hematopoiesis and Induction of Apoptosis Involve But Are Not Limited to a Nitric Oxide Pathway. <i>Blood</i> 90, 217-225 (1 July 1997).	
	BA	Lee, J.W. et al. HLA-DR-Triggered Inhibition of Hemopoiesis Involves Fas/Fas Ligand Interactions and is Prevented by c-kit Ligand. <i>J. Immunol.</i> 159, 3211-3219 (1997).	
BB	Masuda, M. et al. Dual action of CD30 antigen: Anti-CD30 antibody induced apoptosis and interleukin-8 secretion in Ki-1 lymphoma cells. <i>Int. J. Hematol.</i> 67, 257-265 (April 1998).		
BC	McDevitt, H.O. et al. Monoclonal anti-la antibody therapy in animal models of autoimmune disease. <i>Ciba Foundation Symposium</i> 129, 184-193 (1987).		

Form PTO/SB/08		Docket Number (Optional) GPCG-P01-003	Application Number 10/001,934
INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>		Applicant Nagy et al.	
		Filing Date November 15, 2001	Group Art Unit 1642
	BE	Mysler, E. et al. The Apoptosis-1/Fas Protein in Human Systemic Lupus Erythematosus. <i>J. Clin. Invest.</i> 93, 1029-1034 (March 1994).	
	BF	Nakamura, N. et al. Apoptosis in Human Hepatoma Cell Line Induced by 4,5-Didehydrogeranylgeranoic Acid (Acyclic Retinoid) via Down-Regulation of Transforming Growth Factor-alpha. <i>Biochem. Biophys. Res. Comm.</i> 219, 100-104 (1996).	
	BG	Naquet, P. et al. Dissection of the Poly(Glu60 Ala30 Tyr10) (GAT)-Specific T-Cell Repertoire in H-21 Mice. <i>Immunogenetics</i> 18, 559 (1983).	
	BH	Newell, M.K. et al. Ligation of major histocompatibility complex class II molecules mediates apoptotic cell death in resting B lymphocytes. <i>PNAS</i> 10459-10463 (Nov. 1993).	
	BI	Presta, L.G. Antibody engineering. <i>Curr. Op. Struct. Biol.</i> 2, 593-596 (1992).	
	BJ	Rheinnecker, M. et al. Multivalent Antibody Fragments with High Functional Activity for a Tumor-Associated Carbohydrate Antigen. <i>J. Immunol.</i> 157, 2989-2997 (1 Oct. 1997).	
	BK	Riechmann, L. et al. Reshaping human antibodies for therapy. <i>Nature</i> 332, 323-329 (1988).	
	BL	Roos, G. et al. Establishment and Characterization of a Human EBV-Negative B Cell Line (MN 60). <i>Leukemia Res.</i> 6, 685-693 (1982).	
	BM	Slavin-Chiorini, D.C. et al. A CDR-Grafted (Humanized) Domain-Deleted Antitumor Antibody. <i>Cancer Biother. Radiopharm.</i> 12, 305-316 (1997).	
	BN	Stausbol-Gron, B. et al. A model phage display subtraction method with potential for analysis of differential gene expression. <i>FEBS Letters</i> 391, 71 (1996).	
	BO	Tosi, R. et al. Immunochemical Definition of the New DR Specificity 8WDRw13. <i>Immunological Commun.</i> 10, 275-292 (1981).	
	BP	Truman, J.-P. et al. HLA Class II-Mediated Death is Induced Via Fas/Fas Ligand Interactions in Human Splenic B Lymphocytes. <i>Blood</i> 89, (1996).	
	BQ	Vaickus, L. et al. Antiproliferative Mechanism of Anti-Class II Monoclonal Antibodies. <i>Cell. Immunol.</i> 119, 445 (1989).	
	BR	Vidovic, D. et al. Down-regulation of class II major histocompatibility complex molecules on antigen presenting cells after interaction with helper T cells. <i>Eur. J. Immunol.</i> 25, 1326 (1995).	
	BS	Vidovic, D. et al. Down-regulation of class II major histocompatibility complex molecules on antigen-presenting cells by antibody fragments. <i>Eur. J. Immunol.</i> 25, 3349-3355 (1995).	
BT	Vidovic, D. & Toral, J. Selective apoptosis of neoplastic cells by the HLA-DR-specific monoclonal antibody. <i>Cancer Letters</i> 128, 127-135 (1998).		

Form PTO/SB/08		Docket Number (Optional) GPCG-P01-003	Application Number 10/001,934
INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)		Applicant Nagy et al.	
		Filing Date November 15, 2001	Group Art Unit 1642
	BV	Viken H.D. et al. Serologic Subtyping of HLA-DR8 by Means of the Cytotoxic Human Monoclonal Antibody 5643. <i>Human Immunol.</i> 43, 200-206 (July 1995).	
	BW	Virnekas, B. et al. Trinucleotide phosphoramidites: ideal reagents for the synthesis of mixed oligonucleotides for random mutagenesis. <i>Nucl. Acids Res.</i> 22, 5600-5607 (1994).	
	BX	Vollmers, H.P. et al. Apoptosis of Stomach Carcinoma Cells Induced by a Human Monoclonal Antibody. <i>Cancer</i> 76, 550-558 (15 Aug. 1995).	
	BY	Vose, J.M. et al. Phase II Study of Rituximab in Combination with CHOP Chemotherapy in Patients with Previously Untreated, Aggressive Non-Hodgkin's Lymphoma. <i>J. Clin. Oncol.</i> 19, 389-397 (2001).	
	BZ	Wallen-Ohman, M. et al. Antibody-induced apoptosis in a human leukemia cell line is energy dependent: thermochemical analysis of cellular metabolism. <i>Cancer Letters</i> 75, 103-109 (Dec. 1993).	
	CA	Winter, G. et al. Making Antibodies by Phage Display Technology. <i>Annu. Rev. Immunol.</i> 12, 433 (1994).	
EXAMINER 		DATE CONSIDERED 7/12/03	
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.			

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

RECEIVED
 FEB 07 2003
 TECH CENTER 1600/2900